Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang(Sun Yat-sen University), Jianya Zhou(Zhejiang University), Jianying Zhou(Zhejiang University), Jifeng Feng(Nanjing Medical University), Wu Zhuang(Fujian Provincial Cancer Hospital), Jianhua Chen(Hunan Cancer Hospital), Jun Zhao(Peking University Cancer Hospital), Wei Zhong(Peking Union Medical College Hospital), Yanqiu Zhao(Zhengzhou University), Yiping Zhang(Zhejiang Cancer Hospital), Yong Song(Nanjing General Hospital of Nanjing Military Command), Yi Hu(Chinese PLA General Hospital), Zhuang Yu(Affiliated Hospital of Qingdao University), Youling Gong(Sichuan University), Yuan Chen(Huazhong University of Science and Technology), Feng Ye(Fujian Medical University), Shucai Zhang(Beijing Chest Hospital), Lejie Cao(Anhui Provincial Hospital), Yun Fan(Zhejiang Cancer Hospital), Gang Wu(Huazhong University of Science and Technology), Yubiao Guo(Sun Yat-sen University), Chengzhi Zhou(State Key Laboratory of Respiratory Disease), Kewei Ma(Jilin University), Jian Fang(Peking University Cancer Hospital), Weineng Feng(First People's Hospital of Foshan), Yunpeng Liu(China Medical University), Zhendong Zheng(General Hospital of Shenyang Military Region), Gaofeng Li, Ning Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Song(Peking Union Medical College Hospital), Xiaoqing Liu(Chinese PLA General Hospital), Shijun Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Lieming Ding(Betta Pharmaceuticals (China)), Li Mao(Betta Pharmaceuticals (China)), Giovanni Selvaggi(Xcovery (United States)), Xiaobin Yuan(Betta Pharmaceuticals (China)), Yuanqing Fu(Betta Pharmaceuticals (China)), Tao Wang, Shanshan Xiao, Li Zhang(Sun Yat-sen University)
Cited by 136
Abstract
Related Papers
No related papers found
Powered by citation graph analysis